TearLab Corp fka TEAR

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older Newer

ListenToMe

09/01/12 8:03 AM

Post #80

nice day fri!

Wildbilly

08/13/12 8:22 PM

Post #79

Prospectus filed pursuant to Rule 424(b)(3) (424B3)
Date : 08/13/2012 @ 4:31PM
Source : Edgar (US Regulatory)
Stock : Tearlab Corp. (MM) (TEAR)
Quote : 3.34 0.03 (0.91%) @ 5:15PM

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

This Prospectus Supplement No. 9 supplements the prospectus dated April 10, 2012 or the prospectus, which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-175861). This prospectus supplement is being filed to update, amend and supplement the information included or incorporated by reference in the prospectus with the information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 10, 2012 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report to this prospectus supplement.

The prospectus and this prospectus supplement relate to the disposition from time to time by the selling stockholders identified in the prospectus, or their permitted transferees or other successors-in-interest, of an aggregate of 7,692,308 shares of our common stock, including shares issuable upon the exercise of warrants to purchase our common stock. We are not selling any common stock under the prospectus and this prospectus supplement, and will not receive any of the proceeds from the sale of shares by the selling stockholders.

This prospectus supplement should be read in conjunction with the prospectus, which is to be delivered with this prospectus supplement. This prospectus supplement updates, amends and supplements the information included or incorporated by reference in the prospectus. If there is any inconsistency between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common stock is listed on The NASDAQ Capital Market under the symbol “TEAR,” and on the Toronto Stock Exchange under the symbol “TLB.” The last reported sale price of our common stock on The NASDAQ Capital Market on August 10, 2012 was $3.31 per share.

Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading “Risk Factors” beginning on page 5 of the prospectus, and under similar headings in any amendments or supplements to the prospectus, and “Part II — Item 1A — Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 13, 2012

http://ih.advfn.com/p.php?pid=nmona&article=53806275&xref=newsalert

binks

08/08/12 3:52 PM

Post #78

Re: #76: @binks - May bail before EOD

im out

stockmule

08/08/12 3:40 PM

Post #77

Re: #73: @SSP - It's getting hit on the financial report, however

Is their model still to give away the test machines and charge for the tear strips? I bought this way back below $2 and sold on the run up over $4. Might go back in if it drops back to low $2.90 -$3, one concern is always the low volume.

binks

08/08/12 3:23 PM

Post #76

May bail before EOD

should have done so sooner

ktcougar

08/08/12 10:02 AM

Post #75

Re: #73: @SSP - It's getting hit on the financial report, however

Agree! Numbers should really improve in coming Q's

"Our official marketing launch for the TearLab Osmolarity System took place at the ASCRS annual meeting in Chicago in April," said Elias Vamvakas, TearLab's Chief Executive Officer. "We have experienced considerable interest in our technology and, more significantly, a lot of excitement around the role that an
objective diagnostic test like ours plays in a disease that can effect such a high percentage of the population. As we record revenues when a doctor is able to use our device as opposed to when we sell it, our strong sales performance is not yet reflected in our revenues as the timing of CLIA waiver certificate issuance is creating a significant backlog of units that have been sold but not yet activated. To help put that in perspective, of the 177 orders booked for TearLab systems in the U.S. in the first six months of the year, 135 had not been activated as of June 30 and, as a result, have not yet contributed to our top line."

kt

binks

08/08/12 9:47 AM

Post #74

Re: #73: @SSP - It's getting hit on the financial report, however

I'm still holding

SSP

08/08/12 9:44 AM

Post #73

Re: #72: @binks - damn down hard today

It's getting hit on the financial report, however I think it's a good report. Sellers/shorters aren't looking close enough or reading the report, just seeing a loss and hit it.

binks

08/08/12 9:35 AM

Post #72

damn down hard today

binks

08/07/12 9:38 AM

Post #71

Getting killed today, hope its not an earnings indicator

beach_trades

08/06/12 9:52 PM

Post #70

Re: #64: @TheFinalCD - definately on a TEAR

North Shore Eye Care Announces Comprehensive Dry Eye Treatment Services

July 30, 2012

North Shore Eye Care, a leading eye care provider in the North East, is now offering complete dry eye services, including advanced testing and a wide range of the treatment options. Now utilizing the TearLab Osmolarity System, the physicians at North Shore Eye Care provide patients with precise information about the quality of their tears and progression of dry eye syndrome. With this quantified information, they are able to prescribe the most effective treatment available.

North Shore Eye Care has been serving Long Island communities for 50 years, and is regarded as one of the nations most reputable eye care centers. The physicians specialize in LASIK surgeries, and also provide complete vision care including treatment of blepharitis, glaucoma, and dry eye. Their commitment to using the most advanced technology, has allowed them to offer some of the best care for dry eye, one of the most under-diagnosed vision disorders.

The TearLab Osmolarity System is considered one of the most advanced methods for the diagnosis of dry eye, and has received widespread recognition, including the Medical Design Excellence Award. The physicians at North Shore Eye Care prescribe a well-rounded approach to dry eye treatment, and offer solutions such as artificial tears, Restasis, punctal plugs, and dietary and environmental modifications. Individuals who are interested in learning more about dry eye disease, including its diagnosis and treatment, are encouraged to contact the vision professionals at North Shore Eye Care.

http://www.nseye.com/

beach_trades

07/25/12 6:44 PM

Post #69

Re: #68: @spidaman - Cj do you know what site Sheff uses

His Brain lol

We have the DD here, we should be past $4 soon IMO

spidaman

07/24/12 9:47 PM

Post #68

Re: #67: @beach_trades - We going to new levels soon IMO :)

Cj do you know what site Sheff uses for his stats in his DD posts? I can't ask him because my membership is free which prevents me from posting on his board. Thanks in advance.

beach_trades

07/24/12 2:35 AM

Post #67

Re: #60: @ListenToMe - RECAP....

We going to new levels soon IMO :)

http://online.wsj.com/mdc/public/page/2_3062-shtnasdaq_T-listing.html

1.7 million trapped short

17 day cover

Weekly shows picture nicely

http://stockcharts.com/freecharts/gallery.html?tear

Once it Breaks 4.88-5.14 are it true blue sky

Wrinkles

07/17/12 9:10 PM

Post #66

I'm late to the party, but took Cj's tip to grab some TEAR, bought 3K shares to poke and hope with, will grab more tomorrow.

ListenToMe

07/14/12 8:11 AM

Post #65

Re: #64: @TheFinalCD - definately on a TEAR

Hopefully you got in at $1 BUCK when I first alerted TEAR was about to breakout!!

Keep Making that $$$$$$$ :)

.

TheFinalCD

07/12/12 10:42 AM

Post #64

Re: #62: @ListenToMe - another nice day for TEAR!!

definately on a TEAR

mlkrborn

05/01/12 2:23 PM

Post #63

TearLab study on potential impact of pre-operative osmolarity on LASIK outcomes to be presented (TEAR) 4.10 : Patients with pre-operative hyperosmolarity demonstrated significantly worse UCVA at three months post-surgery (20/28 for hyperosmolar patients vs. 20/19 for normal subjects; p=0.018). All subjects enrolled in the study had the same visual acuity up to one month while they were on a suite of therapies including corticosteroids and Blink Tears. However, once therapy became uncontrolled, the vision of patients with pre-operative hyperosmolarity regressed significantly. These patients averaged a score of 0.2 out of 4 for ocular surface staining before surgery, making it virtually impossible to distinguish any differences between the two groups using that diagnostic method.

ListenToMe

04/28/12 6:56 AM

Post #62

another nice day for TEAR!!

ListenToMe

04/16/12 3:45 PM

Post #61

ListenToMe

04/15/12 7:21 AM

Post #60

RECAP....

ListenToMe Share Wednesday, December 07, 2011 12:29:23 PM
Re: None Post # of 59

The campaign for TEAR to $3.00 BUCKS has begun!!$$$$$$
-------------------------------------------------------------------------------------------------------------------------------------

TEAR closed $4.37 Friday and exceeded my short term Target!

Yaaaaayyyyy for me!!!!! AND ALL US TEAR SHAREHOLDERS!!!!

.

mlkrborn

04/11/12 11:00 AM

Post #59

Stox sale @ $3.60 but trading @ $4 today!
TearLab prices underwritten public offering of 3 mln shares of its common stock at $3.60/share for gross proceeds of $10.8 mln (TEAR) 3.70 :

deadboy

03/27/12 9:25 AM

Post #58

Good morning TEAR! Aother 52 week high today?

ListenToMe

03/26/12 10:00 PM

Post #57

Re: #55: @deadboy - New 52 week high! BOOYAH! :-)

I second that!!

deadboy

03/26/12 6:59 PM

Post #56

TEAR is 100% buy!

http://barchart.com/opinions/stocks/tear

deadboy

03/26/12 12:56 PM

Post #55

New 52 week high! BOOYAH! smile

deadboy

03/25/12 10:17 PM

Post #54

To the moon tomorrow big smile

ListenToMe

03/24/12 8:25 AM

Post #53

I told you guys this thing can and WILL move on air and now we are almost into Floating mode once we get into the stratosphere!!!

ListenToMe

03/24/12 8:24 AM

Post #52

Re: #51: @beach_trades - Blue Sky Air!

Beautiful Day!!!!! :)

beach_trades

03/23/12 9:17 PM

Post #51

Re: #41: @ListenToMe - I'm telling you this thing moves on air!

Blue Sky Air!

mlkrborn

03/23/12 4:57 PM

Post #50

TearLab Announces Warrant Exercise by Institutional Investors
GlobeNewswirePress Release: TearLab Corporation – Mon, Mar 19, 2012 8:00 AM EDT

RELATED QUOTES
Symbol Price Change
TEAR 3.62 +0.72

SAN DIEGO, March 19, 2012 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR - News) (TSX:TLB.TO - News) ("TearLab" or the "Company") announced today that 1,373,700 share purchase warrants issued in connection with the Company's June 2011 private placement financing have been exercised by certain institutional investors into an equivalent number of common shares of the Company for total gross proceeds of approximately $2,555,000. Approximately 2,472,454 share purchase warrants issued in connection with the June 2011 financing remain outstanding.

"We would like to thank our shareholders for their continued confidence and support," commented Elias Vamvakas, TearLab's Chief Executive Officer. "These warrant exercises have satisfied our immediate funding needs in a non-dilutive way. While we would still like to have additional financial resources to pursue some of our slated marketing and sales programs, and to complete the development of our second test, we plan on being strategic in the way that we achieve that. As always, we remain committed to building shareholder value while, at the same time, minimizing shareholder dilution."

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

stockmule

03/23/12 12:45 PM

Post #49

Re: #48: @stockmule - Let's see where this holds. I did shed

The gaps in the chart had me thinking a pull back was coming but we are now forming a cup and handle breakout, this could rock higher.

stockmule

03/22/12 10:36 AM

Post #48

Let's see where this holds. I did shed some tears today. Revs should pick up going forward but I don't expect the stock price to reflect it until we get close to the next Q.

Penny Roger$

03/22/12 1:09 AM

Post #47

Re: #46: @Penny Roger$ - ~ Thursday! $TEAR ~ Earnings posted, pending or

Penny Roger$

03/22/12 1:08 AM

Post #46

~ Thursday! $TEAR ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $TEAR ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

http://stockcharts.com/h-sc/ui?s=TEAR&p=D&b=3&g=0&id=p88783918276&a=237480049

http://stockcharts.com/h-sc/ui?s=TEAR&p=W&b=3&g=0&id=p54550695994

~ Google Finance: http://www.google.com/finance?q=TEAR
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=TEAR#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=TEAR+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=TEAR
Finviz: http://finviz.com/quote.ashx?t=TEAR
~ BusyStock: http://busystock.com/i.php?s=TEAR&v=2

<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=TEAR >>>>>>

http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

ListenToMe

03/09/12 8:13 PM

Post #45

CRAZY MAN!!!! :)

stockmule

03/09/12 3:56 PM

Post #44

Re: #43: @stockmule - Took this from yahoo board, better discussion going

Wow a 50k share trade at 2.95, thought one that large would surely tank the bid but it didn't. Taking it down on 100s trades again to accumulate more shares it appears. I wonder if we could see 2.40 and then bounce.

stockmule

03/09/12 11:16 AM

Post #43

Re: #42: @stockmule - It's been crazy the last few days..........no news

Took this from yahoo board, better discussion going on over there.

Craig-Hallum Capital has initiated coverage of TearLab (NASDAQ:TEAR; TSX:TLB) with a “buy” rating and 12-month price target of $5, calling the company a “unique diagnostics opportunity with ophthalmology.” The stock was changing hands at $2 Monday afternoon.
Analyst Steven Crowley writes that TearLab’s Osmolarity System offers optometrists and ophthalmologists a unique point-of-care diagnostic tool for fast, easy, and quantitative diagnosis and monitoring of Dry Eye Disease (DED).
It features “compelling economics for physicians, modest cost for payors, is FDA-approved and CLIA-waived, and recent developments have removed major obstacles to market access and reimbursement,” he added. “We believe TearLab is poised to drive widespread adoption of its novel razor/razorblade system, ultimately establishing the TearLab Osmolarity System as the standard-of-care for diagnosis of DED.”
Based on feedback from physicians, Mr. Crowley sees “this reality translating to a rapidly growing and very profitable entity of significant size in atypically short order.”
He figures that if only 10% of the U.S. patient population were tested and monitored annually, TearLab’s revenue from disposables alone would be $80 million, comprised of four million people times two eyes times $10 per test.
“With a clear path to 50%-plus gross margins, we believe that’s an equation likely to generate exceptional investment returns for a company with a market cap currently below $40 million,” he added.